Effect of interferon on the health‐related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan–prednisone to melphalan–prednisone + α‐interferon

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 2, 1996-08 ,pp. : 324-332

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 314-319

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immortal time bias and reverse causality in retrospective analysis: Comment on “effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib–melphalan–prednisone in the phase III VISTA study”

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 8, 2015-08 ,pp. : E146-E146

John Wiley & Sons Inc

Access to resources Recommend Favorite

The efficacy of a health‐related quality‐of‐life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: results of a multicentre randomized controlled trial

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 4, 2015-10 ,pp. : 1091-1094

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial

By Kavanaugh Arthur   Menter Alan   Mendelsohn Alan   Shen Yaung-Kaung   Lee Seina   Gottlieb Alice B.  

Current Medical Research and Opinion, Vol. 26, Iss. 10, 2010-10 ,pp. : 2385-2392

Informa Healthcare

Access to resources Recommend Favorite